Affordable Access

deepdyve-link
Publisher Website

Deubiquitylating enzymes as cancer stem cell therapeutics.

Authors
  • Haq, Saba1
  • Suresh, Bharathi2
  • Ramakrishna, Suresh3
  • 1 Department of Lifesciences, College of Natural Sciences, Hanyang University, Seoul, South Korea. , (North Korea)
  • 2 Department of Pharmacology and Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: [email protected] , (North Korea)
  • 3 Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, South Korea; College of Medicine, Hanyang University, Seoul, South Korea. Electronic address: [email protected] , (North Korea)
Type
Published Article
Journal
Biochimica et Biophysica Acta
Publisher
Elsevier
Publication Date
Jan 01, 2018
Volume
1869
Issue
1
Pages
1–10
Identifiers
DOI: 10.1016/j.bbcan.2017.10.004
PMID: 29054474
Source
Medline
Keywords
License
Unknown

Abstract

The focus of basic and applied research on core stem cell transcription factors has paved the way to initial delineation of their characteristics, their regulatory mechanisms, and the applicability of their regulatory proteins for protein-induced pluripotent stem cells (protein-IPSC) generation and in further clinical settings. Striking parallels have been observed between cancer stem cells (CSCs) and stem cells. For the maintenance of stem cells and CSC pluripotency and differentiation, post translational modifications (i.e., ubiquitylation and deubiquitylation) are tightly regulated, as these modifications result in a variety of stem cell fates. The identification of deubiquitylating enzymes (DUBs) involved in the regulation of core stem cell transcription factors and CSC-related proteins might contribute to providing novel insights into the implications of DUB regulatory mechanisms for governing cellular reprogramming and carcinogenesis. Moreover, we propose the novel possibility of applying DUBs coupled with core transcription factors to improve protein-iPSC generation efficiency. Additionally, this review article further illustrates the potential of applying DUB inhibitors as a novel therapeutic intervention for targeting CSCs. Thus, defining DUBs as core pharmacological targets implies that future endeavors to develop their inhibitors may revolutionize our ability to regulate stem cell maintenance and differentiation, somatic cell reprogramming, and cancer stem cells.

Report this publication

Statistics

Seen <100 times